HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity
| Status: | Completed |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 11/30/-0001 |
| Start Date: | March 2012 |
| End Date: | January 2014 |
| Contact: | Paula J Allen, MA |
| Email: | paula.allen2@va.gov |
| Phone: | 405-456-3982 |
An Investigator-initiated Pilot Study Using Statins to Improve the Anti-HCV Response to Peginterferon Alfa 2-b and Ribavirin in Previous Non-responders
Objective: The goal is to improve peginterferon sensitivity in previous poor responders.
"Sensitivity" here means the host's ability to kill more HCV.
Design: Twenty poor responders to prior PIFN/RBV will be given 48 weeks of statin
monotherapy. Veterans and civilians between the ages of 18 and 70 are eligible.
Inclusion Criteria:
Hepatitis C positive by HCV RNA within 180 days. - No anti-HCV medicine within 30 days of
screening
Exclusion Criteria:
- decompensated liver disease
- severe cardiac disease (ejection fraction < 20% or uncontrolled angina)
- unexplained muscle pain at time of screening
- pregnancy
- renal insufficiency (creatine clearance < 50 ml/min)
We found this trial at
1
site
Click here to add this to my saved trials
